Graph AI, a California-based AI life sciences company focused on patient safety and pharmacovigilance, has raised $3 million in its seed funding round led by Bessemer Venture Partners.
The funds raised will be used to accelerate product innovation, expand its engineering team, and drive global market adoption.
Founded in 2024 by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO), Graph AI is a California-based AI life sciences company focused on patient safety and pharmacovigilance.
Graph AI operates in the $8 billion pharmacovigilance market, a regulatory process where pharmaceutical companies track and report adverse drug events (ADEs) throughout a drug’s lifecycle.
Pharmacovigilance, mandated by global drug regulatory authorities, requires pharmaceutical companies to continuously monitor, detect, and report adverse drug events (ADEs) across a drug’s entire lifecycle, from clinical trials to post-market use, ensuring patient safety and regulatory compliance.
The company’s flagship platform, Graph Safety, is redefining pharmacovigilance through context-aware artificial intelligence and intelligent automation, delivering a truly end-to-end safety solution. Already deployed with leading enterprise customers, Graph Safety automates key processes including ADE case processing, signal detection, aggregate reporting, and regulatory compliance, while building a centralized safety intelligence database over time.
By keeping a human-in-the-loop only for select regulatory-mandated steps, Graph enables pharmaceutical companies to transition from manual, error-prone, and time-intensive workflows to highly automated, AI-driven systems that enhance the efficiency and accuracy of medical reviews while ensuring full regulatory compliance.
In just over a year since its inception, Graph AI has delivered remarkable traction and tangible results. Its proprietary AI models demonstrate exceptional accuracy, ensuring consistent classification and complete data extraction from both structured and unstructured sources.
Today, Graph’s platform has built a strong pipeline across more than 7,000 marketed drugs.
Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, founders of Graph AI, said, “The life sciences industry continues to grapple with outdated technology, fragmented point solutions, data silos, and manual handoffs that hinder decision-making and elevate compliance risks. At Graph AI, we’re addressing these challenges with a unified, AI-native safety platform that integrates context, compliance, and intelligence into a single seamless ecosystem. Our vision is to make patient safety smarter, faster, and more connected, empowering pharmaceutical and biotech enterprises to achieve safer outcomes, stronger regulatory confidence, and exponential efficiency across safety operations.”
Nithin Kaimal, Partner and COO at Bessemer Venture Partners India, said, “We’re excited to partner with Graph AI as they redefine labour-intensive and inefficient pharmacovigilance workflows through AI-native solutions that prioritize both accuracy and scalability. At Bessemer, we’re deeply optimistic about the transformative potential of AI products to reimagine traditional services models, as for the first time, delivery is shifting from labour arbitrage to intelligence arbitrage, empowering enterprises to work with firms that deliver faster, smarter, and more adaptive solutions. We look forward to supporting the Graph team as they continue to scale new heights.”
